AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18402944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15837660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia (L group, n=20)
Number of subjects: 40
Study 15837660 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA group, n=20)
Number of subjects: 40
Study 11452703 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 10 mg
Number of subjects: 11
Study 11452703 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 10 mg plus Vitamin K 10 mg
Number of subjects: 11
Study 9610586 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave treatment (n = 125)
Number of subjects: 169
Study 9610586 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (n = 44)
Number of subjects: 169
Study 7528584 — intervention group
Group type: EXPERIMENTAL
Intervention: HHES (hypertonic saline hydroxyethyl starch solution) 4 ml.kg‐1
Number of subjects: 27
Study 7528584 — intervention group
Group type: COMPARATOR
Intervention: HES (control group)
Number of subjects: 27
Study 3228576 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) albuterol 8 mg tablet every 12 h for 8 days
Number of subjects: 15
Study 3228576 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) albuterol 4 mg tablet every 6 h for 8 days
Number of subjects: 15
Study 3228576 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) albuterol
Number of subjects: 15
Study 30716933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-alcohol orange beverage (500 mL/day for 2 weeks)
Number of subjects: 18
Study 30264896 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT LOUD (voice), n = 22
Number of subjects: 64
Study 30264896 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT ARTIC (articulation), n = 20
Number of subjects: 64
Study 30264896 — intervention group
Group type: COMPARATOR
Intervention: UNTXPD (untreated), n = 22
Number of subjects: 64
Study 25784207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion prior to CVC placement in group A (25 patients)
Number of subjects: 67
Study 25784207 — intervention group
Group type: COMPARATOR
Intervention: CVC placement in patients with PLT count above 50×10^9/L (group B, 42 patients)
Number of subjects: 67
Study 24372522 — intervention group
Group type: EXPERIMENTAL
Intervention: Buddhism-based walking meditation (BWM)
Number of subjects: 45
Study 24372522 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional walking exercise (TWE)
Number of subjects: 45
Study 24372522 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 45
Study 22121069 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-minute heart rate variability (HRV)
Number of subjects: 470
Study 19395686 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-contact behavioral treatment (n = 392)
Number of subjects: 785
Study 19395686 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 393)
Number of subjects: 785
Study 17627902 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting beads (DEB) TACE
Number of subjects: 30
Study 16241932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group training (CBGT)
Number of subjects: 107
Study 16241932 — intervention group
Group type: COMPARATOR
Intervention: Blood glucose awareness training (BGAT)
Number of subjects: 107
Study 12134181 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine with adrenaline (1:8,00,000)
Number of subjects: 41
Study 12134181 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lignocaine without adrenaline
Number of subjects: 41
Study 10023791 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (2 puffs: 42 mcg BID)
Number of subjects: 18
Study 10023791 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (2 puffs, 180 mcg QID)
Number of subjects: 18
Study 10023791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10023791 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (2 puffs)
Number of subjects: 18
Study 10023791 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (4 puffs: 84 mcg BID)
Number of subjects: 18
Study 10023791 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (4 puffs)
Number of subjects: 18
Study 10023791 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (4 puffs, 360 mcg BID)
Number of subjects: 18
Study 7753965 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 93,426 (0.04 mg/kg)
Number of subjects: 8
Study 7753965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2325251 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3mg in 10ml of saline solution with epinephrine 50 micrograms added
Number of subjects: 14
Study 2325251 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 3mg in 10ml of saline solution without epinephrine
Number of subjects: 14
Study 34084 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 0
Study 34084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30912701 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 24
Study 30912701 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g L−1)
Number of subjects: 24
Study 30912701 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 g L−1)
Number of subjects: 24
Study 30912701 — intervention group
Group type: COMPARATOR
Intervention: NeuroCart® tests (laboratory tests)
Number of subjects: 24
Study 28012553 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 0
Study 28012553 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 0
Study 25894688 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-management intervention
Number of subjects: 101
Study 25894688 — intervention group
Group type: EXPERIMENTAL
Intervention: External assessments (outside observations and tape recordings)
Number of subjects: 101
Study 25894688 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal evaluation methods (through study nurse forms and notes)
Number of subjects: 101
Study 23708322 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (1.1 g) plus D-chiro-inositol (27.6 mg)
Number of subjects: 0
Study 23708322 — intervention group
Group type: COMPARATOR
Intervention: D-chiro-inositol (500 mg)
Number of subjects: 0
Study 21468753 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 559
Study 21468753 — intervention group
Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 559
Study 19767796 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Training (IT) load
Number of subjects: 18
Study 19767796 — intervention group
Group type: COMPARATOR
Intervention: Normal Training (NT)
Number of subjects: 18
Study 17327247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber enhancements
Number of subjects: 0
Study 17327247 — intervention group
Group type: COMPARATOR
Intervention: Ventricular‐only enhancements
Number of subjects: 0
Study 14985687 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid combined with 0.25 mg vitamin B12 (n=9)
Number of subjects: 42
Study 14985687 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vitamin B6 (n=8)
Number of subjects: 42
Study 14985687 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg vitamin B6 (n=9)
Number of subjects: 42
Study 14985687 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 42
Study 14985687 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg vitamin B6 (n=8)
Number of subjects: 42
Study 11583721 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 5-10 mg/day for 6 months
Number of subjects: 32
Study 11583721 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 32
Study 11583721 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 32
Study 9711804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular rabies vaccine (conventional regimen)
Number of subjects: 1198
Study 9711804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal rabies vaccine (Thai Red Cross schedule)
Number of subjects: 1198
Study 9711804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular rabies vaccine with human or equine rabies immune globulin
Number of subjects: 1198
Study 9711804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal rabies vaccine with human or equine rabies immune globulin
Number of subjects: 1198
Study 7527131 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 99
Study 7527131 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aprotinin
Number of subjects: 99
Study 7527131 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study 2646918 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and treatment for intestinal parasite infection
Number of subjects: 0
Study 2646918 — intervention group
Group type: COMPARATOR
Intervention: Control group (examined at six months only)
Number of subjects: 0
Study 4916790 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (20-30 mg/24 hours, average 29 mg/24 hours for at least 6 months, with some receiving it for longer)
Number of subjects: 125
Study 4916790 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prednisone)
Number of subjects: 125
Study 4916790 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (combined groups)
Number of subjects: 125
Study 29986146 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (420 mL, 8.4 mmol inorganic nitrate (NO3‐)·day‐1)
Number of subjects: 14
Study 29986146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) with depleted NO3‐ (0.01 mmol NO3‐·day‐1)
Number of subjects: 14
Study 29986146 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation
Number of subjects: 14
Study 29986146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 14
Study 28147703 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteal activation group (GLUTE)
Number of subjects: 24
Study 28147703 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 24
Study 25417708 — intervention group
Group type: EXPERIMENTAL
Intervention: MP‐376 (levofloxacin inhalation solution)
Number of subjects: 151
Study 25417708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 23147738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin (with or without antimicrobial baths)
Number of subjects: 1089
Study 23147738 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine body washes
Number of subjects: 1089
Study 21967362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam (2500 mg) with clonazepam (1 mg)
Number of subjects: 0
Study 21967362 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam (1 mg) with placebo
Number of subjects: 0
Study 20029334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis before transplant surgery
Number of subjects: 220
Study 20029334 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 220
Study 20029334 — intervention group
Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 220
Study 17145061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 15063564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent acellular pertussis combined vaccine (DTacP-IPV; Tetravac) as second booster
Number of subjects: 234
Study 15063564 — intervention group
Group type: COMPARATOR
Intervention: Pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac)
Number of subjects: 234
Study 11230379 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to educational information during computerized order entry
Number of subjects: 45
Study 11230379 — intervention group
Group type: COMPARATOR
Intervention: Standard order entry on paper chart (Control)
Number of subjects: 45
Study 9696501 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol chemoembolization plus tamoxifen (40 mg)
Number of subjects: 73
Study 9696501 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 73
Study 7853154 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 0
Study 7853154 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running
Number of subjects: 0
Study 7853154 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking and running
Number of subjects: 0
Study 7853154 — intervention group
Group type: COMPARATOR
Intervention: Overground walking and running
Number of subjects: 0
Study 2675599 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal dexamethasone
Number of subjects: 147
Study 2675599 — intervention group
Group type: COMPARATOR
Intervention: Calf-lung surfactant extract alone
Number of subjects: 147
Study 2675599 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf-lung surfactant extract and dexamethasone
Number of subjects: 147
Study 2675599 — intervention group
Group type: COMPARATOR
Intervention: Calf-lung surfactant extract
Number of subjects: 147
Study 1107893 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 110
Study 1107893 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 110
Study 31804680 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc Poudrage (4 g during thoracoscopy under moderate sedation)
Number of subjects: 330
Study 31804680 — intervention group
Group type: COMPARATOR
Intervention: Talc Slurry (4 g via bedside chest tube with local anesthesia)
Number of subjects: 330
Study 29922895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 180
Study 29922895 — intervention group
Group type: COMPARATOR
Intervention: No tranexamic acid (noTXA)
Number of subjects: 180
Study 29307999 — intervention group
Group type: EXPERIMENTAL
Intervention: dexlansoprazole 60 mg
Number of subjects: 175
Study 29307999 — intervention group
Group type: COMPARATOR
Intervention: esomeprazole 40 mg
Number of subjects: 175
Study 29307999 — intervention group
Group type: COMPARATOR
Intervention: none
Number of subjects: 175
Study 25931290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment (SADE)
Number of subjects: 44
Study 25931290 — intervention group
Group type: COMPARATOR
Intervention: Regular Dental Environment (RDE)
Number of subjects: 44
Study 22954234 — intervention group
Group type: COMPARATOR
Intervention: Excel stents
Number of subjects: 346
Study 22954234 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual DES
Number of subjects: 346
Study 21310075 — intervention group
Group type: EXPERIMENTAL
Intervention: Open MR scanner
Number of subjects: 2000000
Study 21310075 — intervention group
Group type: COMPARATOR
Intervention: Closed short-bore MR scanner with 97% noise reduction
Number of subjects: 2000000
Study 19578654 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimization procedure for treatment allocation
Number of subjects: 0
Study 19578654 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered arrival order of patients
Number of subjects: 0
Study 16430775 — intervention group
Group type: EXPERIMENTAL
Intervention: Misola (731 +/- 7 kcal/day)
Number of subjects: 550
Study 16430775 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiruline plus traditional meals (748 +/- 6 kcal/day)
Number of subjects: 550
Study 16430775 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiruline plus Misola (767 +/- 5 kcal/day)
Number of subjects: 550
Study 16430775 — intervention group
Group type: COMPARATOR
Intervention: Traditional meals only (722 +/- 8 kcal/day)
Number of subjects: 550
Study 14993087 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy activities to counter environmental-level smoking influences
Number of subjects: 10
Study 14993087 — intervention group
Group type: COMPARATOR
Intervention: Drug and alcohol abuse prevention education
Number of subjects: 10
Study 14993087 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy activities
Number of subjects: 10
Study 15229337 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP19 11‐repeat alleles (2 alleles)
Number of subjects: 173
Study 15229337 — intervention group
Group type: COMPARATOR
Intervention: CYP19 11‐repeat alleles (0 alleles)
Number of subjects: 173
Study 15229337 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Met/Met genotype
Number of subjects: 173
Study 15229337 — intervention group
Group type: COMPARATOR
Intervention: COMT Val/Val genotype
Number of subjects: 173
Study 15229337 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Val/Val genotype with at least one CYP19 11‐repeat allele
Number of subjects: 173
Study 15229337 — intervention group
Group type: COMPARATOR
Intervention: Neither genotype/allele
Number of subjects: 173
Study 10977012 — intervention group
Group type: EXPERIMENTAL
Intervention: L+G (insulin lispro + glyburide)
Number of subjects: 135
Study 10977012 — intervention group
Group type: COMPARATOR
Intervention: NPH+G (bedtime NPH insulin + glyburide)
Number of subjects: 135
Study 10977012 — intervention group
Group type: EXPERIMENTAL
Intervention: All therapies
Number of subjects: 135
Study 9384424 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 40 mg methylprednisolone with 1% lidocaine
Number of subjects: 58
Study 9384424 — intervention group
Group type: COMPARATOR
Intervention: Saline solution with 1% lidocaine (control group)
Number of subjects: 58
Study 1586601 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate 25 mg orally daily for 6 months
Number of subjects: 150
Study 1586601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 3543432 — intervention group
Group type: EXPERIMENTAL
Intervention: S6472 (375 mg, 2 times daily for 7 days)
Number of subjects: 248
Study 3543432 — intervention group
Group type: COMPARATOR
Intervention: CCL (250 mg, 3 times daily for 7 days)
Number of subjects: 248
Study 3396471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 2g 8‐hourly
Number of subjects: 75
Study 3396471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin 2g 6‐hourly
Number of subjects: 75
Study 3396471 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (900 mg 8‐hourly) and gentamicin 3 to 5 mg/kg/day in divided doses 8‐hourly
Number of subjects: 75
Study 31804108 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnometry-assisted antihyperventilation respiratory training
Number of subjects: 80
Study 31804108 — intervention group
Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 80
Study 31985099 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (ABL group)
Number of subjects: 85
Study 31985099 — intervention group
Group type: COMPARATOR
Intervention: Conventional pharmacotherapy (CNT group)
Number of subjects: 85
Study 31668885 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM + LF (bovine milk fat globule membrane and lactoferrin in infant formula)
Number of subjects: 451
Study 31668885 — intervention group
Group type: COMPARATOR
Intervention: Control (cow's milk‐based infant formula)
Number of subjects: 451
Study 28151797 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 775
Study 26498227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 0
Study 26498227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23371785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-treated group (beta glucan‐containing oat cereal)
Number of subjects: 34
Study 23371785 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 34
Study 23371785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-treated group
Number of subjects: 34
Study 23371785 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 21549465 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure severity classified using the IDS of the ICED scoring system
Number of subjects: 1846
Study 19438397 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (600 mg per day)
Number of subjects: 142
Study 19438397 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (400 mg per day)
Number of subjects: 142
Study 17447829 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 3-12 mg/day for 6 weeks
Number of subjects: 0
Study 17447829 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 0
Study 17447829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16398720 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenosis group
Number of subjects: 101
Study 16398720 — intervention group
Group type: COMPARATOR
Intervention: Flow group
Number of subjects: 101
Study 16398720 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 11490241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 132
Study 11490241 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 132
Study 9669447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg)
Number of subjects: 20
Study 9669447 — intervention group
Group type: COMPARATOR
Intervention: Urapidil (30 mg)
Number of subjects: 20
Study 8001719 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (volunteers for military service)
Number of subjects: 145
Study 8001719 — intervention group
Group type: COMPARATOR
Intervention: Group B (non-volunteers for military service)
Number of subjects: 145
Study 3354367 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (emergency surgery)
Number of subjects: 15
Study 3354367 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 15
Study 30632220 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian root extract (VRE) 100 mg thrice daily
Number of subjects: 64
Study 30632220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29245275 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus radiotherapy (60-66 Gy/30 to 33 fractions)
Number of subjects: 88